STUDY ON SIDDHA MEDICINE TO MANAGE AND TREAT MENTAL AND BEHAVIOURAL PROBLEMS IN CHILDREN

CLINICAL EVALUATION AND THERAPEUTIC MANAGEMENT OF MANTHA SANNI(AUTISM SPECTRUM DISORDER) WITH AMUKKARA CHOORANAM AND YEGAMOOLI THYLAM THUVALAI IN CHILDREN

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/12/022286

Enrollment

Registered

2019-12-10

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F01-F99- Mental, Behavioral and Neurodevelopmental disorders

Interventions

Intervention1: Amukkara chooranam yegamooli thylam: Amukkara chooranam 3-4 yrs 300mg 5-7 yrs 500mg 8-12 yrs 1gm yegamooli thylam as external application Intervention2: Amukkara chooranam yegamooli thy

Eligibility

Inclusion criteria

Inclusion criteria: Clinically diagnosed as autism spectrum disorder ASD Meets diagnostic symptoms of poor eye contact inappropriate emotional response acquired speech or lost it engages in stereotyped and repetitive behaviour unusual sensitive to sensory stimuli

Exclusion criteria

Exclusion criteria: The conditions that co occur with ASD Attention deficit hyperactivity disorder ADHD Cerebral palsy Hearing and visual impairments congenital anomalies Any other serious illness

Design outcomes

Primary

Measure	Time frame
Efficacy of the trial drug is assessed by indian scale for assesement of autismTimepoint: 90 days	—

Secondary

Measure	Time frame
Reduction in the symptoms and improvement in quality of life of childrenTimepoint: 90 days	—

Countries

India

Contacts

Public ContactDR M MEENAKSHI SUNDARAM

National Institute of Siddha

mmssiddha@gmail.com9940266442

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026